An announcement from Bausch Health Companies ( (TSE:BHC) ) is now available.
Bausch Health Companies, along with its gastroenterology business Salix Pharmaceuticals, announced that the U.S. District Court ruled in favor of the FDA, Salix, and Teva, denying Norwich Pharmaceuticals’ motion for a preliminary injunction regarding the approval of a generic version of XIFAXAN® (rifaximin). This decision supports Bausch Health’s continued market position and access to XIFAXAN, a key product for treating hepatic encephalopathy and irritable bowel syndrome with diarrhea, until at least 2028.
Spark’s Take on TSE:BHC Stock
According to Spark, TipRanks’ AI Analyst, TSE:BHC is a Neutral.
Bausch Health Companies’ stock is moderately rated mainly due to solid revenue growth and cash flow generation. However, high leverage, negative equity, and profitability issues weigh heavily. Technical indicators show neutral momentum, while valuation is unattractive due to negative earnings. Positive earnings call and corporate events provide some optimism, but financial stability concerns remain prevalent.
To see Spark’s full report on TSE:BHC stock, click here.
More about Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified pharmaceutical company focused on delivering better healthcare outcomes. The company develops, manufactures, and markets products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health, with a controlling interest in Bausch + Lomb Corporation.
YTD Price Performance: -43.32%
Average Trading Volume: 2,886,992
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.68B
For an in-depth examination of BHC stock, go to TipRanks’ Stock Analysis page.